Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | AbbVie Inc | 987 |
| 2 | Samsung Biologics Co Ltd | 900 |
| 3 | Bristol Myers Squibb Co | 685 |
| 4 | Bayer AG | 658 |
| 5 | University of California | 582 |
| 6 | Roche Holding AG | 497 |
| 7 | BASF SE | 486 |
| 8 | Massachusetts Institute of Technology | 486 |
| 9 | Medtronic PLC | 476 |
| 10 | Johnson and Johnson | 380 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 38,135 |
| 2 | A61P | Therapeutic activity (drug indications) | 34,228 |
| 3 | C07K | Peptides | 11,918 |
| 4 | C12N | Microorganisms, enzymes | 10,564 |
| 5 | C07D | Heterocyclic compounds | 10,213 |
| 6 | Y02A | Climate change adaptation | 8,232 |
| 7 | G01N | Investigating / analysing materials | 5,105 |
| 8 | A61L | Sterilising / disinfecting materials | 4,412 |
| 9 | C12Q | Measuring/testing involving enzymes | 3,972 |
| 10 | A01N | Preservation of bodies; biocides; pest repellents | 3,617 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Palatable trimethoprim oral solution | 1997 | Alkermes PLC | 26 |
| Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use | 1994 | Novartis AG | 25 |
| Tablets comprising trimethoprim and a sulfonamide | 1986 | Astellas Pharma Inc | 13 |
| Solution containing trimethoprim, sulfacetamide and polymyxin | 1976 | GSK PLC | 13 |
| Tablets containing trimethoprim, sulphamethoxazole and polyvinylpyrrolidone | 1981 | 12 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 87 |
| 2017 | 84 |
| 2018 | 84 |
| 2019 | 68 |
| 2020 | 74 |
| 2021 | 75 |
| 2022 | 90 |
| 2023 | 68 |
| 2024 | 45 |
| 2025 | 16 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Sherry F. Queener | Indiana University – Purdue University Indianapolis | 42 |
| 2 | Aleem Gangjee | Duquesne University | 27 |
| 3 | Rudolf Then | Roche (Switzerland) | 16 |
| 4 | Allan Ronald | University of Manitoba | 14 |
| 5 | R. N. Grüneberg | University College London | 13 |
| 6 | S. G. B. Amyes | University of London | 12 |
| 7 | W. Brumfitt | University College London | 11 |
| 8 | J. Feeney | National Institute for Medical Research | 11 |
| 9 | Tom Bergan | University of Oslo | 10 |
| 10 | J. M. T. Hamilton‐Miller | University College London | 10 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Projections of Global Mortality and Burden of Disease from 2002 to 2030 | 2006 | 11544 | Global Maternal and Child Health |
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | 1985 | 2649 | Protein Structure and Dynamics |
| Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system | 1988 | 2065 | Protein Structure and Dynamics |
| Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis | 2002 | 962 | Liver Disease and Transplantation |
| Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies | 1984 | 859 | HIV/AIDS drug development and treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of trimethoprim?
Which companies hold the most patents related to trimethoprim?
What are the most prolific authors in trimethoprim research?
What are the primary patent classifications for trimethoprim inventions?
What notable scientific papers discuss trimethoprim's mechanism of action?